| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acute liver graft rejection after ipilimumab therapy
|
Dueland, S.
|
|
|
28 |
10 |
p. 2619-2620
|
article
|
| 2 |
Annals of Oncology:un bon travail
|
Soria, J.C.
|
|
|
28 |
10 |
p. 2337-2339
|
article
|
| 3 |
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
|
Calvo, E.
|
|
|
28 |
10 |
p. 2559-2566
|
article
|
| 4 |
An unknown reaction to pembrolizumab: giant cell arteritis
|
Micaily, I.
|
|
|
28 |
10 |
p. 2621-2622
|
article
|
| 5 |
An update of the WCRF/AICR systematic literature review and meta-analysis on dietary and anthropometric factors and esophageal cancer risk
|
Vingeliene, S.
|
|
|
28 |
10 |
p. 2409-2419
|
article
|
| 6 |
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
|
Kasper, B.
|
|
|
28 |
10 |
p. 2399-2408
|
article
|
| 7 |
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
|
Dunn, L.A.
|
|
|
28 |
10 |
p. 2533-2538
|
article
|
| 8 |
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin
|
Bossi, P.
|
|
|
28 |
10 |
p. 2547-2551
|
article
|
| 9 |
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
|
Cohen, E.E.W.
|
|
|
28 |
10 |
p. 2526-2532
|
article
|
| 10 |
Blood- and tissue-based tumor genomics: a battle royale or match made in heaven?
|
Hahn, A.W.
|
|
|
28 |
10 |
p. 2333-2335
|
article
|
| 11 |
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
|
Bellmunt, J.
|
|
|
28 |
10 |
p. 2481-2488
|
article
|
| 12 |
Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013
|
Islami, F.
|
|
|
28 |
10 |
p. 2567-2574
|
article
|
| 13 |
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial
|
Gleeson, M.
|
|
|
28 |
10 |
p. 2511-2516
|
article
|
| 14 |
Changes in the use of end points in clinical trials for elderly cancer patients over time
|
Le Saux, O.
|
|
|
28 |
10 |
p. 2606-2611
|
article
|
| 15 |
Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primaryEGFR mutation plus secondaryMET amplification and a novel acquired crizotinib-resistant mutationMET G1108C
|
Li, Y.Q.
|
|
|
28 |
10 |
p. 2622-2624
|
article
|
| 16 |
Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies
|
Ross, J.S.
|
|
|
28 |
10 |
p. 2539-2546
|
article
|
| 17 |
DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
|
Martinez-Marti, A.
|
|
|
28 |
10 |
p. 2451-2457
|
article
|
| 18 |
Editorial board
|
|
|
|
28 |
10 |
p. ii-iii
|
article
|
| 19 |
ESMO-Magnitude of Clinical Benefit Scale version 1.1
|
Cherny, N.I.
|
|
|
28 |
10 |
p. 2340-2366
|
article
|
| 20 |
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
|
Shi, Y.K.
|
|
|
28 |
10 |
p. 2443-2450
|
article
|
| 21 |
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
|
Schultheis, B.
|
|
|
28 |
10 |
p. 2429-2435
|
article
|
| 22 |
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium
|
Quaglino, P.
|
|
|
28 |
10 |
p. 2517-2525
|
article
|
| 23 |
Guideposts on the journey to value
|
Schilsky, R.L.
|
|
|
28 |
10 |
p. 2325-2326
|
article
|
| 24 |
Human papillomavirus-related oropharyngeal cancer
|
Taberna, M.
|
|
|
28 |
10 |
p. 2386-2398
|
article
|
| 25 |
Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer
|
Sciallero, S.
|
|
|
28 |
10 |
p. 2620-2621
|
article
|
| 26 |
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters
|
Linch, M.
|
|
|
28 |
10 |
p. 2472-2480
|
article
|
| 27 |
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
|
Azria, D.
|
|
|
28 |
10 |
p. 2436-2442
|
article
|
| 28 |
Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the International STEP Study
|
Molassiotis, A.
|
|
|
28 |
10 |
p. 2552-2558
|
article
|
| 29 |
Midostaurin: a magic bullet that blocks mast cell expansion and activation
|
Valent, P.
|
|
|
28 |
10 |
p. 2367-2376
|
article
|
| 30 |
Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance
|
Barata, P.C.
|
|
|
28 |
10 |
p. 2458-2463
|
article
|
| 31 |
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
|
Beköz, H.
|
|
|
28 |
10 |
p. 2496-2502
|
article
|
| 32 |
Observation as the initial management strategy in patients with mantle cell lymphoma
|
Abrisqueta, P.
|
|
|
28 |
10 |
p. 2489-2495
|
article
|
| 33 |
Of mice and men: patient-derived xenografts in cancer medicine
|
Hochhauser, D.
|
|
|
28 |
10 |
p. 2330-2331
|
article
|
| 34 |
Open access to journal articles in oncology: current situation and citation impact
|
Hua, F.
|
|
|
28 |
10 |
p. 2612-2617
|
article
|
| 35 |
Overcoming barriers to integrating patient-reported outcomes in clinical practice and electronic health records
|
Basch, E.
|
|
|
28 |
10 |
p. 2332-2333
|
article
|
| 36 |
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors
|
Izumchenko, E.
|
|
|
28 |
10 |
p. 2595-2605
|
article
|
| 37 |
Possible macrophage activation in melanoma patients receiving combined kinase inhibitor therapy following anti-PD-1 therapy: a cytokine profiling study of two cases
|
Umemura, H.
|
|
|
28 |
10 |
p. 2624-2625
|
article
|
| 38 |
Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation
|
Takamatsu, H.
|
|
|
28 |
10 |
p. 2503-2510
|
article
|
| 39 |
Reply to the letter to the editor ‘Can we trust burnout research?’ by Bianchi et al.
|
Banerjee, S.
|
|
|
28 |
10 |
p. 2625-2626
|
article
|
| 40 |
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases
|
Sartor, O.
|
|
|
28 |
10 |
p. 2464-2471
|
article
|
| 41 |
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
|
Fujii, T.
|
|
|
28 |
10 |
p. 2420-2428
|
article
|
| 42 |
Right–left or midgut–hindgut?
|
Valentí, V.
|
|
|
28 |
10 |
p. 2618
|
article
|
| 43 |
Risk of age-related macular degeneration in patients with prostate cancer: a nationwide, population-based cohort study
|
Lin, S.-Y.
|
|
|
28 |
10 |
p. 2575-2580
|
article
|
| 44 |
Secondary CNS lymphoma: the poisoned needle in the haystack
|
Ferreri, A.J.M.
|
|
|
28 |
10 |
p. 2335-2337
|
article
|
| 45 |
Table of Contents
|
|
|
|
28 |
10 |
p. iv-vii
|
article
|
| 46 |
‘Thursday’s child has far to go’—interpreting subgroups and the STAMPEDE trial
|
Spears, M.R.
|
|
|
28 |
10 |
p. 2327-2330
|
article
|
| 47 |
Treatment of squamous cell carcinoma of the anal canal (SCCA): a new era?
|
Casadei Gardini, A.
|
|
|
28 |
10 |
p. 2620
|
article
|
| 48 |
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
|
Khoja, L.
|
|
|
28 |
10 |
p. 2377-2385
|
article
|
| 49 |
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
|
Chapman, P.B.
|
|
|
28 |
10 |
p. 2581-2587
|
article
|
| 50 |
Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001
|
Churilla, T.M.
|
|
|
28 |
10 |
p. 2588-2594
|
article
|
Journal description